Gilead Sciences Touts Encouraging Data From Real World Studies Of Its Flagship COVID-19 Treatment
$GILD
$SRNE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Commercial Physical & Biological Resarch
Health Care
- Gilead Sciences Inc (NASDAQ:GILD) announced data from three retrospective real-world Veklury (remdesivir) studies for COVID-19 treatment.
- The studies demonstrated that initiating Veklury within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity.
- A reduction in mortality was also observed in vulnerable populations.
- Related: WHO Recommends Gilead's COVID-19 Therapy For Severe Disease.
- Two studies analyzed clinical practice information from the U.S. Premier Healthcare databases of more than 500,000 adult patients hospitalized with COVID-19.
- For patients with no documented use of supplemental oxygen at baseline, treatment with Veklury was associated with a 19% lower risk of mortality at Day 28.
- Patients on low-flow or high-flow oxygen also had a 21% and 12% lower mortality risk at Day 28, respectively.
- Patients on invasive mechanical ventilation/ECMO at baseline had a 26% reduced risk for mortality at Day 28.
- These findings were observed throughout all variant periods, including Omicron, in patients who did not require supplemental oxygen and across all levels of supplemental oxygen use.
- A separate analysis found that hospitalized patients with COVID-19 treated with Veklury were also significantly less likely (27%) to be readmitted within 30 days to the same hospital.
- Based on in vitro analyses, Veklury retains potent antiviral activity against recent Omicron subvariants of concern.
- Price Action: GILD shares are down 0.38% at $84.32 on the last check Wednesday.